Core Insights - Reckitt has undergone significant transformation since its last appearance at CAGNY in 2024, including a strategy update and successful execution of that plan [1] - The company has achieved asset sales, productivity savings, and strong performance in its core brands like Lysol and Mucinex [1][2] - Complexity within the organization has been reduced, enhancing earnings visibility and accelerating growth [2] Strategic Developments - The company is at a critical inflection point, indicating a pivotal moment in its strategic evolution [2] - Future plans and strategies leading up to 2026 are anticipated to be discussed, highlighting Reckitt's ongoing commitment to growth and adaptation [2]

A SIMPLER, SHARPER RECKITT CAGNY 19th February 2026 CAUTIONARY NOTE CONCERNING FORWARD –LOOKING STATEMENTS This presentation and any other information discussed at the presentation (collectively, the "presentation") has been prepared by Reckitt Benckiser Group plc (the "Company") solely for your information. The opinions presented herein are based on general information gathered at the time of writing and are subject to change without notice. Information in this presentation sourced from third parties has b ...

Austin, Feb. 17, 2026 (GLOBE NEWSWIRE) -- The Disinfectant Chemicals Market size was valued at USD 6.57 Billion in 2025 and is expected to reach USD 10.60 Billion by 2033 and grow at a CAGR of 6.18% from 2026 to 2033. The market for disinfectant chemicals is expanding due to rising healthcare-associated infection cases, rising public awareness of cleanliness and hygiene, and strict sanitation laws in hospitals, food processing facilities, and commercial buildings. Download PDF Sample of Disinfectant Chemic ...

Group 1: E-commerce and Market Growth - L'Oréal highlighted that e-commerce is transforming its reach in India, allowing the company to connect with previously underserved markets and accelerate growth [2] - Unilever noted that India is well positioned for medium-term growth, with rapid gains in e-commerce and quick commerce offsetting short-term GST impacts [2] - Reckitt Benckiser reported that its quick commerce business in India is more than doubling this year, with Flipkart growing at 30 percent [3] Group 2: Revenue and Performance Insights - Westinghouse Air Brake Technologies Corporation stated that year-to-date, its like-for-like net revenue growth in India remains at high single-digits, expecting the recent slowdown to be a matter of phasing [4] - TransUnion mentioned that India's growth was slightly below expectations due to tariff-related pressures but reaffirmed confidence in the market's long-term potential [5] - Visteon Corporation is deepening its presence in India with new digital products and expanded manufacturing plans [6] Group 3: Manufacturing and Export Developments - Westinghouse secured $140 million in brake orders driven by increased activity in India, marking a significant milestone for its Marhowrah plant [4] - BE Semiconductor Industries noted that India is emerging as a key location for new assembly capacities as customers diversify from China, with five major customers setting up assembly capacities in the country [8] - CIE Automotive emphasized that India remains one of its strongest and most stable markets, reinforcing its global importance [9] Group 4: Automotive Market Position - India has consolidated its position as the world's third-largest automotive market, surpassing Japan with nearly 25 million vehicles a year and continuing to grow across all segments [9]

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Reckitt Benckiser Group plc regarding a class action lawsuit alleging that the company made materially false and misleading statements about its Enfamil formula, which is linked to increased risks for preterm infants [1][2]. Group 1: Allegations and Class Period - The class period for the allegations is from January 13, 2021, to July 28, 2024 [1]. - The allegations include that Reckitt's cow's milk-based formula, Enfamil, posed an increased risk of developing NEC in preterm infants, which was not disclosed [1]. - The lawsuit claims that Reckitt's positive statements about its business and operations were materially false and misleading due to the undisclosed risks and potential legal claims [1]. Group 2: Next Steps for Shareholders - Shareholders who purchased shares of RBGLY during the specified timeframe are encouraged to register for the class action by August 4, 2025 [2]. - Upon registration, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case [2]. - There is no cost or obligation for shareholders to participate in the case [2]. Group 3: About the Gross Law Firm - The Gross Law Firm is a nationally recognized class action law firm focused on protecting investors' rights against deceit and fraud [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements [3].

Core Viewpoint - A class action lawsuit has been filed against Reckitt Benckiser Group plc for allegedly misleading investors regarding the risks associated with its cow's milk-based formula, Enfamil, during the class period from January 13, 2021, to July 28, 2024 [1][4]. Company Overview - Reckitt Benckiser Group plc is a UK-based global consumer goods company facing over 500 state and federal product liability lawsuits related to its cow's milk-based formula, Enfamil, and its competitor Abbott Laboratories' Similac [3]. Legal Allegations - The class action lawsuit claims that Reckitt made misleading statements and omissions about its business and financial condition, specifically failing to disclose the increased risk of necrotizing enterocolitis (NEC) for preterm infants consuming its formula [4]. - The lawsuit alleges that Reckitt did not adequately warn investors about the potential impact on sales and legal exposure related to the NEC risk associated with its products [4].

Core Viewpoint - The Gross Law Firm has issued a notice to shareholders of Reckitt Benckiser Group plc regarding a class action lawsuit related to misleading statements and omissions concerning the company's cow's milk-based formula, Enfamil, which allegedly increased the risk of NEC in preterm infants [1][3]. Group 1: Allegations and Class Period - The class period for the lawsuit is defined as January 13, 2021, to July 28, 2024 [3]. - Allegations include that Reckitt failed to disclose the increased risk of NEC for preterm infants consuming Enfamil, the impact on sales, and the exposure to legal claims, leading to materially false and misleading statements about the company's business and prospects [3]. Group 2: Shareholder Actions - Shareholders are encouraged to register for the class action by the deadline of August 4, 2025, to potentially become lead plaintiffs [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's status [4]. Group 3: Law Firm's Mission - The Gross Law Firm aims to protect investors' rights and ensure companies adhere to responsible business practices, seeking recovery for losses incurred due to misleading statements or omissions [5].

NEW YORK, July 15, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Reckitt Benckiser Group plc ("Reckitt Benckiser Group plc" or the "Company") (OTC PINK: RBGLY) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Reckitt Benckiser Group plc investors who were adversely affected by alleged securities fraud between January 13, 2021 and July 28, 2024. Follow the link below to get more information and be contacted by a member of our team: ht ...

Core Insights - Reckitt Benckiser Group plc has qualified to trade on the OTCQX® Best Market, upgrading from the Pink® market, which enhances its visibility and accessibility for U.S. investors [1][3][4] - The trading symbols for Reckitt on OTCQX are "RBGLY" and "RBGPF," with current financial disclosures available on the OTC Markets website [2] - The upgrade to OTCQX signifies Reckitt's commitment to transparency and adherence to high financial standards and corporate governance practices [3][4] Company Overview - Reckitt is known for its consumer health and hygiene brands, including Dettol, Durex, Finish, Gaviscon, Harpic, Lysol, Mucinex, Nurofen, Strepsils, Vanish, and Veet, focusing on innovative, science-backed solutions for healthier living [4][5] - The company's mission is to protect, heal, and nurture, aiming for a cleaner and healthier world while expanding access to healthcare and driving sustainable innovation [5][6] Industry Context - OTC Markets Group Inc. operates regulated markets for trading 12,000 U.S. and international securities, providing a platform for companies to access U.S. financial markets efficiently [7][8]